Business · 17/02/2022Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to BioNTech for COVID-19 Vaccine
Summary
The FDA has issued a priority review voucher to BioNTech Manufacturing GmbH for its COVID-19 vaccine, COMIRNATY, which was approved in 2020 and meets the criteria for a material threat medical countermeasure.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →